Phase II Trial Compares FOLFOX8 and mFOLFOX6 in Metastatic Colorectal Cancer
A phase II trial is underway to compare the efficacy and safety of FOLFOX8 versus mFOLFOX6 with bevacizumab or cetuximab in patients with unresectable metastatic colorectal cancer.
Phase II
unresectable metastatic colorectal cancer
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase II trial comparing FOLFOX8 and mFOLFOX6 could significantly impact treatment protocols in colorectal cancer, influencing market dynamics for involved therapies. Monitoring the trial's outcomes is crucial for strategic planning and potential partnerships in this therapeutic area.
Recommended action
Humanexa recommends Monitor: Monitoring is recommended due to the trial's potential impact on competitive positioning and treatment protocols, necessitating close attention to its outcomes and milestones.
Analysis
Key milestones include enrollment completion, interim results on progression-free survival, and overall survival rates.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.